Pharmacovigilance System Transfer is a complex yet increasingly relevant process in today’s regulatory and business environment. The scope of transfer may vary a lot from full PV system to the transfer of one team or process. Pharmaceutical companies might need to transfer a PV system due to mergers and acquisitions, outsourcing, organizational restructuring, or a need to comply with evolving global regulations with the aim to enhance the operational efficiency. In an industry as dynamic and heavily regulated as pharmaceuticals, timely and well-planned PV system transfers are instrumental in enabling companies to meet global standards, manage safety effectively, and remain competitive.
Webinar seeks to share knowledge on key considerations for any PV system change.
Join us: 28 November at 12:00 EET- register to attend.
Presenter: Ada Stelmakienė, Head of Pharmacovigilance | Insuvia: pharmacovigilance professional with 10 years of experience in industry. QPPV office experience ranging from global literature monitoring, cases, signal management and evaluation of benefit-risk profile of medicine to acting as an QPPV for couple of companies. As being involved in a range of PV activities including QPPV function, the PV system transfer is an evitable part of the role.
Ada currently is responsible for the management and oversight of Pharmacovigilance Department to ensure operational excellence and professional grow of all team.
Agenda:
- Goals of PV system transfer
- Key considerations on each PV system transfer phase
- Challenges & Solutions
- Key Points To Success
- Checklist for the Transfer
- Q&A
Language: English | Duration: up to 30 min. | The webinar is free of charge.
